A study by Corey et al. demonstrated that four- to six-week-old severe combined immunodeficient (SCID) mice, intratibially injected with OPG-transfected C4-2 cells (a subline of prostate cancer cells), had higher bone mineral density (BMD), percentage of trabecular bone volume, as well as decreased osteoblast and osteoclast numbers compared to the animals intratibially injected with pcDNA-C4-2 tumors. The gene discussed is TNFRSF11B; the disease is prostate cancer.